VelaVigo is a leading biotech company specializing in the discovery and development of multispecific antibodies and ADCs. Backed by a highly efficient drug discovery platform and strong capabilities in translational medicine, CMC, and early clinical development, VelaVigo has built a robust pipeline of over ten FIC/BIC multispecific antibodies and ADC candidates, with a strategic focus on oncology and autoimmune diseases.


Since its inception in 2021, VelaVigo has completed three major financing rounds with a total of $160 million funding. VelaVigo has successfully established a sustainable “BD+VC” model. In November 2024, the company entered into an out-licensing agreement with U.S.-based Avenzo valued at $800 million, with a $50 million upfront and near-term milestone payment. In April 2025, VelaVigo signed a second out-licensing deal with the U.S. company Ollin, valued at $440 million. These landmark partnerships highlight the technological strength and commercial value of VelaVigo’s innovative pipeline.


In 2025, VelaVigo’s core R&D programs advanced into clinical development in both China and the U.S. The company will continue to expand strategic partnerships across technology platforms, clinical development, and capital markets to maximize R&D efficiency and return on investment.

VelaVigo

Jing Li

This department provides strategic direction and overall management for the organization.

Executive Leadership

This department oversees employee management, recruitment, training, and organizational development.

VelaVigo

Org chart

Teams

Executive Leadership

Human Resources

Offices

VelaVigo

Org chart

Teams

Executive Leadership

Human Resources

Offices

Related companies